Replies to post #14030 on Nutra Pharma Corp (NPHC)

[cngreen]

NPHC's FDA Orphan designation is going to really reduce the costs associated with a Phase 2 and 3 trial. Add Dr VanderPutten and his contacts with government and universities and the recent Manufacturing Alliance With Omnia Biologics to Produce RPI-78M for Clinical Trials will reduce costs even further.

NPHC is moving forward with their drugs again. IMO, shares are on sale at these prices.